Generic drug capsules. Photo: Anton Vergun/TASS via Getty Images

Many generic drugs are "wildly overpriced" in Medicare, according to a new analysis of federal data from research firm 46brooklyn Research.

Why it matters: Health insurers and pharmacy benefit managers manipulate generic drug prices in Medicaid, and it appears more generics gaming occurs in Medicare — all on the back of taxpayers and patients.

How it works: Medicare drug plans are buying many generics at prices that are significantly above their ingredient costs.

  • Because plans can't conduct "spread pricing" in Medicare, they claw back money from pharmacies, based on those inflated prices, through different means.
  • Example: A common dose of antipsychotic drug aripiprazole costs $0.30 per pill, but the median Medicare drug plan priced it at $2.58 per pill in the first quarter of this year, according to 46brooklyn's analysis. A handful of companies priced it at more than $20 per pill.
  • 46brooklyn's data can't pinpoint where those margins are going. But pharmacies almost certainly aren't keeping big chunks, given how Medicare plans are increasingly clawing back money from them over the past few years.

Go deeper: Explore the data from the study

Go deeper

Court battles shift mail-in voting deadlines in battleground states

Illustration: Sarah Grillo/Axios

Michigan joins Pennsylvania in extending mail-in ballot deadlines by several days after the election, due to the coronavirus pandemic and expected delays in U.S. Postal Service.

The latest: Michigan Court of Claims Judge Cynthia Stephens ruled that all ballots postmarked before Nov. 2 must be counted, so long as they arrive in the mail before election results are certified. Michigan will certify its general election results on Nov. 23.

Ina Fried, author of Login
7 mins ago - Technology

Interview: Unity CEO explains his company's unusual IPO

CEO John Riccitiello virtually ringing the NYSE bell as Unity shares began trading on Friday. PhotoL Unity

Unity Technologies was just one of many companies with blockbuster IPOs this week, but it took a decidedly different approach, using data rather than handshakes to decide who got to invest and at what price. CEO John Riccitiello explained why in an interview with Axios.

Why it matters: Traditionally, bankers and companies set IPO prices based on conversations and expectations, a process that has been criticized as basically leaving money on the table.

8 mins ago - Podcasts

Taylor Lorenz on Trump's threat to ban TikTok

President Trump has 48 hours left to either follow through on his threatened ban of TikTok, or accept a proposed tech partnership with Oracle.

Axios Re:Cap digs into how the TikTok user community has reacted to this political drama, and what comes next, with New York Times tech reporter Taylor Lorenz.